Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -96.23M | -95.79M | -101.32M | -101.26M | -114.33M |
| Total Depreciation and Amortization | 2.20M | 6.02M | 4.94M | 2.47M | 2.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.85M | 19.99M | 15.08M | 19.03M | 21.69M |
| Change in Net Operating Assets | -37.17M | 494.00K | 4.41M | -19.87M | -58.78M |
| Cash from Operations | -117.35M | -69.29M | -76.90M | -99.62M | -148.93M |
| Capital Expenditure | -79.00K | -126.00K | -29.00K | -239.00K | -735.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.39M | 27.66M | -712.00K | 107.15M | 95.06M |
| Cash from Investing | 66.31M | 27.53M | -741.00K | 106.91M | 94.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 33.57M | 1.98M | 114.86M | 14.65M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 33.57M | 1.98M | 114.86M | 14.65M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.47M | -39.77M | 37.22M | 21.94M | -54.60M |